This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Cramer's 'Mad Money' Recap: Once Hated, Now Loved

Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.

NEW YORK ( TheStreet) -- Investors are like most TV watchers, always changing channels, Jim Cramer told his "Mad Money" TV show viewers Thursday. He opined about a multitude of stocks that were once hated but are now loved as investors have once again changed their minds.

No stock illustrates this move better than Facebook (FB), a stock Cramer owns for his charitable trust, Action Alerts PLUS . Cramer said that after the worst IPO in history, Facebook has emerged as the king of mobile and social advertisers. He's still a buyer of Facebook, along with Google (GOOG).

Other sectors that are getting a second look include travel, thanks to TripAdvisor (TRIP), and the airlines, with US Airways (LCC) leading the charge.

Biotech remains a hot sector, with Cramer recommending Celgene (CELG) and Regeneron (REGN) as just two of many faves. He was also bullish on housing, despite disappointments from D.R. Horton (DHI). He said that news won't affect ancillary housing stocks such as Home Depot (HD) and Restoration Hardware (RH).

Other Cramer faves include the autos, banks and oil and gas stocks, along with some technology and semiconductor names. Cramer even had kind words for Starbucks (SBUX) and Dunkin' Brands (DNKN).

Executive Decision: Tarek Sherif

In the "Executive Decision" segment, Cramer spoke with Tarek Sherif, founder, chairman and CEO of Medidata Solutions (MDSO), the cloud computing provider to the health care industry that's seen it shares rise by 30% since Cramer last spoke with Sherif just six weeks ago.

Sherif said the Food and Drug Administration is mandating that the industry change the way it performs clinical trials, and Medidata is the prime beneficiary of that mandate. He said by using modern cloud technology, Medidata is driving value by improving the quality of trials with less risk and helping to bring better drugs to market faster.

Sherif said clinical trials are still largely in the early stages of using technology, but those that have embraced the technology are getting through their trials faster. He said Medidata has a terrific business model where 80% to 90% of its revenue stems from repeat customers.

1 of 3

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,279.74 +13.75 0.08%
S&P 500 2,010.40 -0.96 -0.05%
NASDAQ 4,579.7870 -13.6380 -0.30%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs